09:17 AM EDT, 09/23/2024 (MT Newswires) -- Cosciens Biopharma ( CSCI ) on Monday said it hired an executive recruiting firm to recruit the company's next president and chief executive.

Cosciens also said the initial integration of Ceapro, which it acquired in June, is progressing well. Cost cutting measures have begun, including efforts to "right size" the combined business through the elimination of a number of managerial and technical positions.

The company is reviewing the results from the Phase 3 DETECT-Trial of macimorelin for the treatment of childhood growth hormone deficiency (CGHD), after reporting last month that top-line results of the trial showed that the primary efficacy endpoint had not been met.

Cosciens will discontinue further spending on the preclinical research program to evaluate the potential use of macimorelin for the treatment of amyotrophic lateral sclerosis (ALS).

"The ALS program has taken far longer and will cost more than was first anticipated and the company does not have sufficient confidence from the data obtained to date that it will ultimately provide the much needed treatment for ALS patients that it once hoped," said CEO Gilles Gagnon.